Announcement: After some experimentation, we will be moving the publication to a wednesday, and will have the most current opportunities contained within.

🧬 Precision Oncology: FDA Approves First ADC for Ultra-Rare Blood Cancer
On May 27, the FDA granted priority review approval to AbbVie's pivekimab sunirine-pvzy (Decnupaz). This marks the arrival of the first antibody-drug conjugate (ADC) specifically targeting CD123 for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)—an ultra-rare and highly aggressive hematologic malignancy that routinely defies conventional chemotherapy regimens.

🧪 Obesity Management: Eli Lilly's Retatrutide Delivers Bariatric-Surgery-Level Weight Loss
Eli Lilly published historic Phase 3 results from its TRIUMPH-1 trial for retatrutide. The triple hormone receptor agonist (targeting GIP, GLP-1, and glucagon receptors) demonstrated unprecedented weight reduction metrics, establishing a new pharmacological baseline that rivals the efficacy of surgical bariatric intervention.

🫀 Cardiology Practice Shock: Global Study Finds Beta-Blockers "Useless" Post-Infarction
A massive international clinical trial has upended 40 years of standard cardiac care guidelines. The landmark study revealed that routine, long-term prescription of beta-blockers for patients who suffered a heart attack but maintained normal heart function offers no survival benefit and may introduce unnecessary side effects, prompting an immediate re-evaluation of post-MI care pathways.

💼 Mega-Financing: Apogee and Blackstone Form $1.3B Strategic Alliance for Phase 3 Tech
On May 27, Apogee Therapeutics announced a massive $1.3 billion strategic financing collaboration with Blackstone Life Sciences. The capital injection is explicitly structured to accelerate the Phase 3 development and rapid commercialization of zumilokibart, an advanced monoclonal antibody aiming to disrupt the highly competitive immunology and dermatology landscapes.

🫁 Rare Diseases: FDA Accepts BridgeBio Application for Novel Muscular Dystrophy Drug

BridgeBio Pharma announced on May 28 that the FDA has accepted its filing for a potential first-in-class therapeutic addressing limb-girdle muscular dystrophy. The regulatory milestone brings the rare disease space closer to its first approved disease-modifying treatment for a condition that historically relied solely on palliative physical therapy.

📊 Population Genomics: GSK Plugs into Singapore's SG100K Precision Medicine Engine
The precision medicine ecosystem in Asia gained significant momentum as GSK officially joined the PRECISE-SG100K partner program. The multinational pharmaceutical giant will collaborate on advancing population-scale proteomics and genomic mapping within multi-ethnic Asian cohorts, driving highly targeted therapeutic discovery for region-specific disease profiles.

🫀 Autoimmune Care: J&J’s Tremfya Becomes Only IL-23 Inhibitor Proven to Halt Joint Damage
On May 28, Johnson & Johnson secured a major FDA label expansion for guselkumab (Tremfya). Backed by 24-week data from the Phase 3b APEX study, it is now officially the only IL-23 inhibitor clinically proven to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, heavily differentiating it in the rheumatology workflow.

🧬 M&A In Genetic Delivery: Eli Lilly Acquires Non-Viral DNA Platform Biotech
Consolidating its lead in genetic medicine, Eli Lilly completed its seventh acquisition of the year by buying preclinical developer Engage Biologics for up to $202 million. The acquisition centers on Engage's proprietary Tethosome platform, a novel system that pairs lipid nanoparticles with mRNA-encoded components to significantly boost the precision and expression strength of non-viral DNA therapeutics.

🧠 Alzheimer’s Disease: USC Researchers Identify Novel Neuro-Inflammation Switch
Scientists at the University of Southern California (USC) discovered a previously hidden biological trigger behind the chronic brain inflammation that accelerates Alzheimer's disease. Alongside the discovery, the team identified small-molecule compounds capable of shutting down this specific inflammatory pathway, opening up an entirely new pipeline for early-stage neurodegenerative drug discovery.

📊 Regulatory Horizon: Bayer's Kerendia Grabbing Priority Review for Type 1 Diabetes
Bayer announced that the FDA has accepted a supplemental New Drug Application and granted Priority Review for finerenone (Kerendia). Already utilized in Type 2 diabetes care, this accelerated review positions the asset to potentially become the first approved drug to slow chronic kidney disease progression specifically in patients with Type 1 diabetes.

🧪 Metabolism Science: NIH Uncovers the Mechanism Behind GLP-1 Weight-Loss Plateaus
A new National Institutes of Health (NIH) study has finally cracked open the mystery of why weight loss plateaus occur during long-term semaglutide therapy. The research demonstrated that GLP-1 receptor agonists trigger highly divergent cellular adaptations over time within appetite-controlling brain networks, providing a biological blueprint for designing next-generation combination therapies to bypass the plateau.

🧬 Oncology Innovation: McGill Scientists Supercharge NK Cells to Penetrate Tumor Defenses
Immunology researchers at McGill University successfully engineered a temporary biological override that prevents Natural Killer (NK) cells from being suppressed by the tumor microenvironment. By supercharging these innate immune cells, the team managed to break down the dense physical and chemical shields that solid tumors use to evade standard immunotherapies.

There are some startups, particularly in healthcare and life sciences working on real life physical therapeutics/care delivery who are under-represented. They often are working on disruptive innovations that affect the substrate level of their sub-industry. This time, I am looking at something a little different, a perinatal platform- Nuumad!

Quick facts:

📰 Website: https://www.nuumad.co.uk/

⚕️ Founded: 2022

👩 Founders: Judit Mora , Nicholas Batten

❤️ Mission: The role of pharmacies within the healthcare system is evolving rapidly. Pharmacists are increasingly providing consultations that previously required GP appointments, helping patients access care more quickly while relieving pressure on primary care services. However, this shift also introduces operational complexity for pharmacies, particularly when managing clinical documentation, compliance requirements and service workflows. Our goal is to build technology that helps pharmacies manage these complexities while expanding their ability to deliver services safely.

🚀 Therapeutic area/ solution: PharmaTech

🤝 Looking for: Visibility

Firstly, we have set the scene. The current medtech focus has been on hospitals and outpatient clinics but often we forget other integral parts of the healthcare journey like the pharmcies! Nuumad. Nuumad helps support Patient Group Directions and helps with clinical workflow orchestration and compliance amongst other things!

How about Nuumad? Nuumad is a UK healthtech platform that helps community pharmacies deliver complex clinical services through safe and user-centred digital consultation workflows. The company is building technology that makes care easier to deliver, while protecting patient safety, clinician confidence and regulatory compliance.

How’s it going/ From the Founders? Within 2.5 years of operating, the company has captured 10% of the UK pharmacy market, with just under 1,000 pharmacies already utilizing its platform, including both large multiples and small independents. Building on this momentum, the company is looking to expand into new markets, driven by a product that has evolved rapidly based on feedback from pharmacists and pharmacy owners. The platform now supports 23 clinical service workflows covering a growing range of private consultations, earning a strong reputation for usability and efficiency by allowing workflows to be completed significantly faster than traditional systems.

This success has fueled organic customer growth largely through word-of-mouth and positive user recommendations across the pharmacy sector. Alongside this market expansion, the company continues to invest heavily in product development, with an upcoming roadmap that includes new automation capabilities, booking system integrations, expanded analytics, improved compliance reporting, and the introduction of independent prescribing modules.

Keen to be featured? Simply fill out this form and we'll be in touch: https://forms.fillout.com/t/oA7knLCbtgus

Listed chronological order (latest at the end!).
When you apply tell the company you heard about the role @ The Fix! (Click for link to listing)

💡Senior Regional Lead | Singapore, Heidi (SG)
💡Head of Growth, Japan (Series C HealthTech), Eucalyptus (JP)
💡Sales and Operations Lead, AMILI (SG)
💡Clinic Operations Associate, Ordinary Folk (SG)
💡Product Manager, BD (SG)
💡Client Success Lead, ThoughtFull (SG)
💡Business Development Manager , Mobio Interactive (USA)
💡Chief Governance Officer/Medical Director, Cordlife (SG)
💡QA/RA, Web Biotechnology Pte Ltd (SG)
💡Product Manager, Early Disease Detection, Mirxes (SG)
💡Sr. Product Manager, iTero Clinical & Lab Solutions, Align Technology, Inc. (SG)
💡Product Manager Software & Clinical Applications, Leica Microsystems (SG)
💡Vice President of Engineering, Universal Health
💡AI Innovation Manager (BC+Hema), Roche (China)
💡Regional Innovation Lead, Consumer Healthcare, MENARINI Group Asia-Pacific
💡Engineering Team Lead - Data2Evidence, Data4Life
💡Clinical Research Coordinator, PHIC, Singapore General Hospital
💡Sponsored PhD Position - Bioacoustic Signal Processing and Machine Learning, Denka Life Innovation Research Pte. Ltd.
💡Finance & Operations Manager, Bot MD
💡Senior Specialist, Product Manager, Clinical Informatics, AIA Singapore (Amplify Health)
💡Assistant Manager/Manager (Medtech, Capability Development and Partnerships), NHIC, CRIS
💡Business Co-founder (Growth/ Partnerships), AuraSense
💡Chief Financial Officer, Cosmetic Physician Partners Asia
💡General Counsel, Cosmetic Physician Partners Asia
💡Co-founder/ Core team member, A*StartCentral (ASPIRE 2026)
💡Head, Bioeconomy Innovation Office, A*STAR
💡LEAD SOFTWARE & HARDWARE ENGINEER (MEDICAL...), Digital Life Line Pte Ltd
💡Senior / Product Manager, MCS, Terumo Asia Pacific
💡Regional Manager, Emergency Care (East Asia), Stryker
💡APAC Government Affairs Leader
💡Associate or Senior Editor, Nature Medicine: Digital Medicine and Artificial Intelligence, Springer Nature
💡Clinical Director, Metabolic Health, Oura
💡Head of Product, Paloma Health
💡Key Account Manager – Rare Diseases, Biomedica GMBH (Kazakhstan)
💡Medical Science Liaison - Rare Disease, AstraZeneca (Taiwan)
💡Medical Science Liaison, Biogen (Tokyo)
💡Product Specialist - Reproductive Health - APJ, Thermo Fisher Scientific (Singapore)

Get your job listed here! Simply fill in the form here

🍵Upcoming Tech Brews meetings (luma.com/techbrews)

🌏 Global MedTech & Health Summits

June 9-12, 2026: Global Health Security Conference Malaysia Focuses on preparedness, prevention, and response to global health threats including pandemics and climate risks. https://ghsn.org/registration/ 

June 10, 2026: NHS Confed Expo UK NHS ConfedExpo is the UK's leading health and care conference, dedicated to driving innovation and improving care for patients and the public.  https://www.nhsconfedexpo.org/ 

June 14, 2026 HLTH Europe 2026 Netherlands Strategic ecosystem event bringing European healthcare leaders together to tackle system-level challenges. https://europe.hlth.com/ 

June 15-18, 2026 HIMSS 26 European Health Conference & Exhibition Denmark Premier European event on digital health adoption, interoperability, AI integration, and workforce transformation. https://himss1.eventsair.com/himss26-europe/programme

July 1, 2026: Smart Health Asia 2026 Singapore Smart Health Asia 2026 is the premier digital health trade show dedicated to transforming healthcare through innovation and collaboration. It is the ultimate meeting place to connect with Asia’s health systems and decision-makers across the ecosystem. https://smarthealthasia.com/registrations/

July 9, 2026: Health Symposium AI Pitch challenge Singapore Participants will have the opportunity to pitch their ideas and receive expert feedback from a panel of judges and industry leaders. The top three teams will gain access to: - Recognition during the symposium - Exclusive networking opportunities with investors and strategic partners - Potential follow-up discussions or funding introductions https://healthsymposium.ai/pitch/

July 16, 2026: Digital Health Summer Schools, Nottingham | 16-17 UK Take part in the premier NHS IT leadership event helping CIOs, CCIOs and CNIOs deliver the shift to community, digitisation and prevention. https://digitalhealthsummerschools.com/

Get your event listed here! Simply fill in the form here